Concerning the fight against breast cancer, doctors have learned an osteoporosis drug appears to reduce a woman's risk for the dreaded disease.

The drug Raloxifene, also known as Evista, reduced the chance of developing breast cancer by over 50-percent in postmenopausal women who weren't at risk for the disease.

The study found it worked even better for women with family histories of breast cancer.

The drug's maker, Eli Lilly, played a role in funding the study.

Right now the FDA hasn't approved the drug for treating breast cancer.

More studies will be done, and that could change.